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DOI: 10.1039/c0jm04194gPlasmon-resonant nanostars (NSTs) provide excellent contrast
enhancement for photoacoustic tomography. The high photo-
acoustic sensitivity of NSTs at near-infrared wavelengths enables
their in vivo detection in rat sentinel lymph nodes and vessels, with
direct application toward lymphangiography.Noninvasive medical imaging systems have been widely used in
clinics to improve diagnostic accuracy and treatment outcomes in
cancer patients.1 Along with the development of imaging techniques,
molecular and nanosized contrast agents have been actively explored
to improve detection sensitivity and specificity in biomedical
imaging.2 Here we demonstrate that plasmon-resonant nanostars
(NSTs) are excellent contrast agents for in vivo photoacoustic
tomography (PAT), with a detection limit at 1 ppm (1 mg mL1)
Au. Gold NSTs have a strong optical response at near-infrared
(NIR) wavelengths, and have been recently deployed as contrast
agents for optical imaging3 and also as substrates for SERS and other
plasmon-enhanced sensing modalities.4 In this article, we use in vivo
spectroscopic PAT to monitor the accumulation of NSTs in the
sentinel lymph nodes (SLNs) of a rat specimen shortly after a footpad
injection, which was later confirmed by ex vivo PAT and inductively
coupled plasma mass spectrometry (ICP-MS).
PAT is a nonionizing, noninvasive, and high-resolution imaging
technique that provides strong optical absorption contrast.5 Since the
spatial resolution of this technique typically depends on ultrasound
(US) parameters, the imaging depth can be extended to the optical
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This journal is ª The Royal Society of Chemistry 2011depth-to-resolution ratio of PAT (defined as the ratio of maximum
penetration depth to depth resolution) is greater than 100 for all
imaging depths. PAT can provide structural information (e.g.,
vascular networks or melanomas) using the intrinsic PA contrast
produced by hemoglobin or melanin, and also functional informa-
tion based on total hemoglobin concentration, oxygen saturation, or
blood flow.5 Exogenous materials such as nanoparticles also play an
important role by enhancing PA contrast for molecular imaging6 and
noninvasive SLN mapping.7 The PA sensitivities for detecting
organic dyes and nanoparticles range from 10 nM at 0.3 mm reso-
lution (1 fmol per imaging voxel) to 10 pM at 0.06 mm resolution
(0.1 attomole per imaging voxel).5 Au-based nanoparticles have
been approved by FDA as drug carriers or therapeutic agents for
various phase-I clinical trials (e.g., http://www.nanospectra.com).
From a clinical perspective, conventional US array systems can be
easily adapted to perform both PA and US imaging, and hand-held,
array-based probes have recently been designed.8
Gold NSTs with an average span of 120 nm (Fig. 1a) were
prepared by a seeded growth method as previously described, starting
from either 13 nm core–shell Fe3O4@Au particles
3,9 (sample A) or
from 8 nm Au particles10 (sample B). Both samples were synthesizedFig. 1 (a) TEM image of plasmon-resonant Au nanostars (NSTs,
sample A). (b) Extinction spectrum of diluted sample A. The absorbance
(arbitrary unit) of the Au nanostars is 0.75 at 767 nm. (c) A plot of
photoacoustic (PA) amplitudes as a function of NST concentration (see
ESI† for details).
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View Article Onlineusing freshly prepared growth solution; NST growth was complete
within 15 minutes after seed addition (see ESI† for details). The
CTAB-stabilized NSTs were purified by treatment with a poly-
styrenesulfonate solution to remove excess CTAB,11 then resus-
pended in 1% bovine serum albumin (BSA) to produce NSTs in their
final, biocompatible form. The extinction spectra of BSA-stabilized
NSTs with and without magnetic cores (Fig. 1b and S1, ESI†)
confirm their strong NIR activities, in accord with earlier reports.3,11
PAT imaging was performed in spectroscopic mode using
a developed deep-reflection modality (see ESI† for details).7 The PA
sensitivity was calibrated using two Tygon tubes, one filled with
aqueous suspensions of NSTs at various concentrations, the other
with defibrinated bovine blood. PA signals from plasmon-resonant
NSTs in tissue phantoms (sample A) were detected at a concentration
of 1 ppm Au with a signal-to-noise ratio of 4 (lex¼ 767 nm; Fig. 1c).
This detection limit corresponds roughly to NST concentrations in
the femtomolar range, with 104 to 105 NSTs per imaging voxel (see
ESI† for details).
The PA contrast was evaluated by performing a volumetric
in vivo mapping of rat lymphatic systems (Fig. 2). Sprague-
Dawley rats were anesthetized according to a standard protocolFig. 2 In vivo photoacoustic (PA) mapping of rat lymphatic systems, enhan
injection, displaying only blood vessels (BV). (b) PA difference image acquire
lymphatic vessels (LV). A separate intensity scale (yellow) was applied to the ly
Photographs of the left axillary region before inoculation with NSTs (top) and
the SLN. (e) Photograph (top) and ex vivo PA image (bottom) of excised SLNs
concentration of NSTs, whereas the SLN from the right axillary region does no
SLNs, 1.5 h after inoculation with NSTs.
2842 | J. Mater. Chem., 2011, 21, 2841–2844(see ESI† for details) with hair removed from the left axillary
region in order to obtain control PA images, prior to the in-
troduction of NSTs (Fig. 2a and d, top). The vascular networks
passing through the axilla are clearly visible due to the intrinsic
PA contrast of hemoglobin, however, neither the lymphatic
vessels nor lymph nodes can be observed.
Rats were then inoculated with an injection of BSA-stabilized
NSTs in the left footpad (0.1 mL of sample A,100 mg Au), and the
left axilla was monitored by in vivo spectroscopic PAT. At 1.5 h post-
injection, the SLN and lymphatic vessels (yellow) clearly stand out
due to the exogenous contrast generated by the NSTs (Fig. 2b). The
SLN is located 1.5 mm below the skin (Fig. S3, ESI†), but can be
clearly resolved by subtracting the control PA image from the post-
injection image (Fig. 2b). A volumetric rendering of the PA contrast
reveals how the blood vessels and lymphatic vasculatures are inter-
woven (Fig. 2c and Movie S1, ESI†). The accumulation of NSTs in
the SLN was visually confirmed after the in vivo imaging study, upon
removal of the skin from the left axillary region (Fig. 2d, bottom). We
note that Au NSTs without Fe3O4 cores produce comparable PA
contrast (see below), as this is derived solely from their plasmon-
resonant optical properties.ced using NSTs (sample A). (a) Control PA image acquired before NST
d post-injection (t ¼ 1.5 h), revealing the sentinel lymph node (SLN) and
mphatic system after subtraction of image (a). (c) 3D rendering of (b). (d)
after in vivo PA imaging (bottom), revealing the accumulation of NSTs in
; the left axillary region (closest to the injection site) contains a visibly high
t. (f) In vivo and ex vivo spectroscopic PA amplitudes measured within the
This journal is ª The Royal Society of Chemistry 2011
Table 1 Photoacoustic (PA) image contrast of NSTs derived from
in vitro, in vivo, and ex vivo studies (sample A, N ¼ 3)
Blood NSTs (ppm Au)
In vitro 5  1 51  3a
In vivo 18  4 59  22b
Ex vivo — 44  21b
a [NST] ¼ 1000 ppm; mean and standard deviation. b NSTs in SLN;
mean and standard error.
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View Article OnlineThe SLNs from the left and right axillae were harvested for ex vivo
spectroscopic PAT. Only the left SLN (closest to injection site)
accumulated an appreciable amount of NSTs, as indicated by both
visual inspection and PA imaging (Fig. 2e). The spectral amplitudes
measured by in vivo and ex vivo imaging produced similar trends (r2¼
0.99), confirming the SLN as the source of PA signal.
Ex vivo PA imaging was also performed at visible wavelengths
(lex ¼ 570 nm) on lymph nodes containing gold NSTs (sample B)
using optical-resolution PA microscopy (see Fig. 3 and ESI†).12 In
addition to confirming their strong PA contrast at shorter wave-
lengths, the microscopic PA image revealed the relative distribution
and density of NSTs throughout the SLN. The NSTs appear to
accumulate in both the subcapsular and trabecular sinuses, implying
their diffusion into successive lymph nodes.
The PA image contrasts from in vitro, in vivo, and ex vivo studies
are compared in Table 1, using an excitation wavelength of 767 nm.
The image contrast is defined simply as (S  B)/B, where S is the
mean PA signal from objects of interest (e.g., SLNs or blood vessels)
and B is the mean background signal. For in vitro imaging, the PA
contrast of NSTs at 1000 ppm Au is10 times stronger than that of
whole blood, whereas in vivo studies indicate the mean PA contrast of
NSTs accumulated in SLNs (1.5 h after injection) to be 3 times
stronger than that of nearby blood vessels. The ex vivo PA contrast
produced from NSTs in excised SLNs (an average weight of50 mg)
was similar to that above; ICP-MS analysis indicated a loading of
42  16 ppm Au, corresponding to a mean injected dose percentage
(ID%) of 2%. It should be noted that the NSTs will continue to
migrate from the footpad into the lymphatic system and collect in the
SLN over time, so the dosage of NSTs needed for lymph node
detection is well below the amount used in this study.
Although in vivo and ex vivo spectroscopic PA imaging confirm the
uptake of NSTs in the SLNs, it is worth mentioning that their exci-
tation spectra do not coincide with the initial optical (extinction)
spectrum of the NSTs in solution (Fig. 1b). Reasons for this
discrepancy may be attributed as follows: (i) the NST extinction
spectrum is defined in part by plasmon-resonant scattering, whereas
PA imaging is mostly sensitive to optical absorption; (ii) the NSTs are
likely to be aggregated upon accumulation in SLNs, causing signifi-
cant changes in their collective optical response.13 We note similar
changes in the optical response of NSTs when dispersed into tissue
phantoms (not shown).
Lymph node mapping has become an important objective in the
detection and subsequent prevention of early stage metastases.14 TheFig. 3 (a) Brightfield optical microscopy of an excised SLN, harvested
from a rat specimen 1.5 h after inoculation with solid Au NSTs (sample
B). (b) Ex vivo PA image of the excised SLN, using a micro-PAT system
operating at shorter wavelengths (lex ¼ 570 nm).
This journal is ª The Royal Society of Chemistry 2011measurements above, in conjunction with the PA detection limit
established in Fig. 1 (1 ppm Au), indicate that Au NSTs are well
suited as contrast agents for lymphatic mapping by PAT. We note
that the detection limit for NSTs is similar to that measured from
other types of gold nanoparticles, but many orders of magnitude
lower than those for single-walled carbon nanotubes coated with
indocyanine green, when compared on a per particle basis.15 The
biocompatibility of colloidal Au is already well established, so the use
of Au NSTs as PAT contrast agents may find promise in clinical
cancer applications involving SLN detection.
In summary, we have demonstrated that plasmon-resonant NSTs
can be used with volumetric spectroscopic PAT for non-invasive
in vivo mapping of lymphatic systems. Subcutaneous injections of
NSTs into rat footpads led to their drainage into SLNs and
lymphatic vessels, enabling these to be visualized and distin-
guished from nearby blood vessels. Further improvements in
exogenous PAT contrast are possible by introducing dynamic
modes of contrast based on periodic signal modulation,16 as
recently demonstrated with magnetomotive NSTs3,9 and also
with Au-coated colloidal Fe3O4.
17 Steps taken in this direction
may accelerate the development of NSTs and other nanoparticles
as PAT-based contrast agents for lymphangiography.
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